维普中文期刊产品整合服务
17篇 您的检索式:作者名="Issac W"
    题名 作者 年代 出处 被引量
1Genetic polymorphisms of surfactant protein D rs2243639, Interleukin (IL)-1β rs16944 and IL-1RN rs2234663 in chronic obstructive pulmonary disease, healthy smokers, and non-smokers 显示文摘Issac MS Ashur W Mousa H 2014Mol Diagn Ther2014,18,3:1
2Genetic polymorphisms of surfactant protein D rs2243639,Interleukin(IL)-1beta rs16944and IL-1RN rs2234663in chronic obstructive pulmonary disease,healthy smokers,and non-smokers显示文摘ISSAC M S ASHUR W MOUSA H 2014Mol Diagn Ther2014,18,:1
3Genetic polymorphisms of surfactant protein D rs2243639,interleukin(IL)-1βrs16944and IL-1RN rs2234663 in chronic obstructive pulmonary disease,healthy smokers,and non-smokers显示文摘Issac MS Ashur W Mousa H 2014Mol Diagn Ther2014,18,3:1
4Genetic polymorphisms of surfactant protein D rs2243639, Interleukin (IL)-l显示文摘Issac MS Ashur W Mousa H 2014Mol Diagn Ther2014,18,3:1
5Isotope effect studies of the paramagnetic to ferromagnetic conducting transition of the CMR compounds Lal-xCaxMnO3显示文摘Franck J P Issac I Chen W 1998J Phys Chem Solids1998,59,:1
6Collisional breakup in a quantum system of three charged particles 显示文摘Resigno T N Baertschy M Issacs W A 1999Science1999,286,:1
7Isotope effect studies of the paramagnetic to ferromagnetic conducting transition of the CMR compounds La1-xCaxMnO3显示文摘Frank J P Issac I Chen W 1998J Phys Chem Solids1998,59,10:1
8Genetic polymorphisms of surfactant protein D rs2243639,Interleukin(IL)-1βrs16944 and IL-1RN rs2234663in chronic obstructive pulmonary disease,healthy smokers,and non-smokers显示文摘ISSAC M S ASHUR W MOUSA H 2014Mol Diagn Ther2014,18,:1
9Isotope effect studies of the paramagnetic to ferromagnetic conducting transiton of the CMR compounds La1-xCaxMnO3显示文摘Frank J P Issac I Chen W 1998J Phys Chem Solids1998,59,1012:1
10Evaluation of the accuracy of PMS optical array probes 显示文摘Korolev A V Strapp J W Issac G A 1998Journal of Atmospheric and Oceanic Technology1998,15,:1
11Grain size effect on ferroelectric phase transition in Pb1xBaxTiO3 ceramics显示文摘FRANCK J P ISSAC I CHEN W 1998Journal of physics and Chemistry of Solids1998,59,7:1
12Genetic polymorphisms of surfactant protein D rs2243639,Interleukin(IL)-1βrs16944 and IL-1RN rs2234663 in chronic obstructive pulmonary disease,healthy smokers,and non-smokers显示文摘Issac MS Ashur W Mousa H 2014Mol Diagn Ther2014,18,3:1
13Genetic polymorphisms of surfactant pro-tein D rs2243639, interleukin (IL)-1β rs16944 and IL-IRN rs2234663 in chronic obstructive pulmonary disease, healthy smokers, and non-smokers 显示文摘Issac MS Ashur W Mousa H 2014Mol Diagn Ther2014,18,3:1
14Trust management in ubiquitous computing:A Bayesian approach显示文摘Denko M K Tao S Issac W 2011Computer Communications2011,34,2:1
15Genetic polymorphisms of surfactant protein D rs2243639, Interleukin (lL)-I~ rs16944 and IL-IRN rs2234663 in chronic obstructive pulmonary diseasevhealthy smokers, and non-smokers显示文摘Issac MS Ashur W Mousa H 2014Mol Diagn Ther2014,18,3:1
16Summer aerosol profiles over Algonquin Park, Canada 显示文摘Issac G A Leaitch W R Strapp J W 1986Atmospheric Environment1986,20,1:1
17Health-related quality-of-life and health-utility reporting in critical care显示文摘Mortality is a well-established patient-important outcome in critical care studies.In contrast,morbidity is less uniformly reported(given the myriad of critical care illnesses and complications of each)but may have a common end-impact on a patient’s functional capacity and health-related quality-of-life(HRQoL).Survival with a poor quality-of-life may not be acceptable depending on individual patient values and preferences.Hence,as mortality decreases within critical care,it becomes increasingly important to measure intensive care unit(ICU)survivor HRQoL.HRQoL measurements with a preference-based scoring algorithm can be converted into health utilities on a scale anchored at 0(representing death)and 1(representing full health).They can be combined with survival to calculate quality-adjusted life-years(QALY),which are one of the most widely used methods of combining morbidity and mortality into a composite outcome.Although QALYs have been use for health-technology assessment decision-making,an emerging and novel role would be to inform clinical decision-making for patients,families and healthcare providers about what expected HRQoL may be during and after ICU care.Critical care randomized control trials(RCTs)have not routinely measured or reported HRQoL(until more recently),likely due to incapacity of some patients to participate in patient-reported outcome measures.Further differences in HRQoL measurement tools can lead to non-comparable values.To this end,we propose the validation of a gold-standard HRQoL tool in critical care,specifically the EQ-5D-5L.Both combined health-utility and mortality(disaggregated)and QALYs(aggregated)can be reported,with disaggregation allowing for determination of which components are the main drivers of the QALY outcome.Increased use of HRQoL,health-utility,and QALYs in critical care RCTs has the potential to:(1)Increase the likelihood of finding important effects if they exist;(2)improve research efficiency;and(3)help inform optimal management of critically ill patients allowing for decision-making about their HRQoL,in additional to traditional health-technology assessments.Vincent Issac Lau Jeffrey A Johnson Sean M Bagshaw Oleksa G Rewa John Basmaji Kimberley A Lewis M Elizabeth Wilcox Kali Barrett Francois Lamontagne Francois Lauzier Niall D Ferguson Simon J W Oczkowski Kirsten M Fiest Daniel J Niven Henry T Stelfox Waleed Alhazzani Margaret Herridge Robert Fowler Deborah J Cook Bram Rochwerg Feng Xie 2022World Journal of Critical Care Medicine2022,11,4:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费